Effect of Simvastatin on Glioma Cell Proliferation, Migration, and Apoptosis

Overview

Journal Neurosurgery

Specialty Neurosurgery

Date 2009 Nov 26

PMID 19934968

Citations 36

Authors

Hongtao Wu

Hao Jiang

Dunyue Lu

Ye Xiong

Changsheng Qu

Dong Zhou

Asim Mahmood

Michael Chopp

Affiliations

Soon will be listed here.

Abstract

Objective: In this study, we investigated the effects of simvastatin on proliferation, migration, and apoptosis in human U251 and U87 glioma cells and the underlying molecular mechanism.

Methods: We used colony formation assay to test the cell proliferation, in vitro scratch assay to examine the cell migration, and caspase-3 activity assay, annexin V staining, and cytochrome C release to evaluate the cell apoptosis. Lipid raft fractions were isolated from glioma cells. Total cholesterol content assay was used to test the change of cholesterol level in lipid raft fractions. Immunocytochemistry staining was performed to detect the changes of lipid rafts in cell membranes. Western blotting analysis was performed to examine the signal transduction both in cells and in lipid raft fractions.

Results: Simvastatin inhibited proliferation and migration of U251 and U87 cells dose dependently. Simvastatin induced an increase of caspase-3 activity and annexin V staining, and down-regulated the phosphatidylinositol 3-kinase (PI3K)/Akt pathway. Simvastatin also decreased cholesterol content in lipid raft fractions, suppressed caveolin-1 expression in the lipid rafts, and induced Fas translocation into lipid rafts, suggesting that simvastatin may inhibit the prosurvival PI3K/Akt pathway and trigger caspase-3-dependent apoptotic cell death through the modulation of lipid rafts.

Conclusion: These results suggest that modulation of lipid rafts, Fas translocation, and PI3K/Akt/caspase-3 pathway are involved in the antitumor effect of simvastatin and may have a potential role in cancer prevention and treatment.

Citing Articles

Effect of Statin Lipophilicity on the Proliferation of Hepatocellular Carcinoma Cells.

Glebaviciute G, Vijaya A, Preta G Biology (Basel). 2024; 13(6).

PMID: 38927335 PMC: 11200858. DOI: 10.3390/biology13060455.

Effects of Simvastatin on Gene Expression and Alkaline Phosphatase Activity in the MG-63 Cell Line Treated With Hyperglycemia for Bone Regeneration.

Inbarajan A, S M, Punnoose A, Gvv G, D A, David J J Cureus. 2024; 16(3):e55482.

PMID: 38571848 PMC: 10989400. DOI: 10.7759/cureus.55482.

Emerging Lipid Targets in Glioblastoma.

Darwish A, Pammer M, Gallyas Jr F, Vigh L, Balogi Z, Juhasz K Cancers (Basel). 2024; 16(2).

PMID: 38254886 PMC: 10814456. DOI: 10.3390/cancers16020397.

Trogocytosis of CAR molecule regulates CAR-T cell dysfunction and tumor antigen escape.

Zhai Y, Du Y, Li G, Yu M, Hu H, Pan C Signal Transduct Target Ther. 2023; 8(1):457.

PMID: 38143263 PMC: 10749292. DOI: 10.1038/s41392-023-01708-w.

Drug Repositioning for Refractory Benign Tumors of the Central Nervous System.

Tamura R Int J Mol Sci. 2023; 24(16).

PMID: 37629179 PMC: 10455557. DOI: 10.3390/ijms241612997.

References

Xia Z, Tan M, Wong W, Dimitroulakos J, Minden M, Penn L . Blocking protein geranylgeranylation is essential for lovastatin-induced apoptosis of human acute myeloid leukemia cells. Leukemia. 2001; 15(9):1398-407. DOI: 10.1038/sj.leu.2402196. View

Roudier E, Mistafa O, Stenius U . Statins induce mammalian target of rapamycin (mTOR)-mediated inhibition of Akt signaling and sensitize p53-deficient cells to cytostatic drugs. Mol Cancer Ther. 2006; 5(11):2706-15. DOI: 10.1158/1535-7163.MCT-06-0352. View

Woodard J, Sassano A, Hay N, Platanias L . Statin-dependent suppression of the Akt/mammalian target of rapamycin signaling cascade and programmed cell death 4 up-regulation in renal cell carcinoma. Clin Cancer Res. 2008; 14(14):4640-9. DOI: 10.1158/1078-0432.CCR-07-5232. View

Prasanna P, Thibault A, Liu L, Samid D . Lipid metabolism as a target for brain cancer therapy: synergistic activity of lovastatin and sodium phenylacetate against human glioma cells. J Neurochem. 1996; 66(2):710-6. DOI: 10.1046/j.1471-4159.1996.66020710.x. View

Denoyelle C, Vasse M, Korner M, Mishal Z, Ganne F, Vannier J . Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits the signaling pathways involved in the invasiveness and metastatic properties of highly invasive breast cancer cell lines: an in vitro study. Carcinogenesis. 2001; 22(8):1139-48. DOI: 10.1093/carcin/22.8.1139. View

Soma M, Pagliarini P, Butti G, Paoletti R, Paoletti P, Fumagalli R . Simvastatin, an inhibitor of cholesterol biosynthesis, shows a synergistic effect with N,N'-bis(2-chloroethyl)-N-nitrosourea and beta-interferon on human glioma cells. Cancer Res. 1992; 52(16):4348-55. View

Pedersen T, Berg K, Cook T, Faergeman O, Haghfelt T, Kjekshus J . Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian Simvastatin Survival Study. Arch Intern Med. 1996; 156(18):2085-92. View

Matthews L, Taggart M, Westwood M . Modulation of caveolin-1 expression can affect signalling through the phosphatidylinositol 3-kinase/Akt pathway and cellular proliferation in response to insulin-like growth factor I. Endocrinology. 2008; 149(10):5199-208. DOI: 10.1210/en.2007-1211. View

Gliemroth J, Zulewski H, Arnold H, Terzis A . Migration, proliferation, and invasion of human glioma cells following treatment with simvastatin. Neurosurg Rev. 2003; 26(2):117-24. DOI: 10.1007/s10143-003-0258-9. View

10.

Koyuturk M, Ersoz M, Altiok N . Simvastatin induces proliferation inhibition and apoptosis in C6 glioma cells via c-jun N-terminal kinase. Neurosci Lett. 2004; 370(2-3):212-7. DOI: 10.1016/j.neulet.2004.08.020. View

11.

Grieb P, Ryba M, Jagielski J, Gackowski W, Paczkowski P, Chrapusta S . Serum cholesterol in cerebral malignancies. J Neurooncol. 1999; 41(2):175-80. DOI: 10.1023/a:1006131418126. View

12.

Aberg M, Wickstrom M, Siegbahn A . Simvastatin induces apoptosis in human breast cancer cells in a NFkappaB-dependent manner and abolishes the anti-apoptotic signaling of TF/FVIIa and TF/FVIIa/FXa. Thromb Res. 2007; 122(2):191-202. DOI: 10.1016/j.thromres.2007.09.017. View

13.

Li Y, Park M, Ye S, Kim C, Kim Y . Elevated levels of cholesterol-rich lipid rafts in cancer cells are correlated with apoptosis sensitivity induced by cholesterol-depleting agents. Am J Pathol. 2006; 168(4):1107-18. PMC: 1606567. DOI: 10.2353/ajpath.2006.050959. View

14.

Cerrato J, Khan T, Koul D, Lang F, Conrad C, Yung W . Differential activation of the Fas/CD95 pathway by Ad-p53 in human gliomas. Int J Oncol. 2004; 24(2):409-17. View

15.

Scheel-Toellner D, Wang K, Singh R, Majeed S, Raza K, Curnow S . The death-inducing signalling complex is recruited to lipid rafts in Fas-induced apoptosis. Biochem Biophys Res Commun. 2002; 297(4):876-9. DOI: 10.1016/s0006-291x(02)02311-2. View

16.

Newman A, Clutterbuck R, Powles R, Millar J . Selective inhibition of primary acute myeloid leukaemia cell growth by simvastatin. Leukemia. 1994; 8(11):2023-9. View

17.

Kondo Y, Hollingsworth E, Kondo S . Molecular targeting for malignant gliomas (Review). Int J Oncol. 2004; 24(5):1101-9. View

18.

Bouterfa H, Sattelmeyer V, Czub S, Vordermark D, Roosen K, Tonn J . Inhibition of Ras farnesylation by lovastatin leads to downregulation of proliferation and migration in primary cultured human glioblastoma cells. Anticancer Res. 2000; 20(4):2761-71. View

19.

Li H, Appelbaum F, Willman C, Zager R, Banker D . Cholesterol-modulating agents kill acute myeloid leukemia cells and sensitize them to therapeutics by blocking adaptive cholesterol responses. Blood. 2002; 101(9):3628-34. DOI: 10.1182/blood-2002-07-2283. View

20.

Keyomarsi K, Sandoval L, Band V, Pardee A . Synchronization of tumor and normal cells from G1 to multiple cell cycles by lovastatin. Cancer Res. 1991; 51(13):3602-9. View